Randomized controlled trials and real life studies. Approaches and methodologies: A clinical point of view.

Pulmonary Pharmacology and Therapeutics

Volumn 27, Issue 2, 2014, Pages 129-138

  Saturni, S ^a   Bellini, F ^a   Braido, F ^b   Paggiaro, P ^c   Sanduzzi, A ^d   Scichilone, N ^e   Santus, P A ^f   Morandi, L ^a   Papi, A ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f IRCCS   (Italy)

Author keywords

Asthma; COPD; Randomized controlled trials; Real life studies

Indexed keywords

AZITHROMYCIN; BCG VACCINE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROLIDE; SALMETEROL;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); EVIDENCE BASED PRACTICE; GOLD STANDARD; HUMAN; INTERNAL VALIDITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; EPIDEMIOLOGY; METHODOLOGY; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ASTHMA; CONFOUNDING FACTORS (EPIDEMIOLOGY); HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84895918167     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2014.01.005     Document Type: Review

References (132)

1. Riegelman R. Studying a study and testing a test: how to read the medical evidence 2000, Lippincott Williams & Wilkins, Philadelphia, PA.
2. Nallamothu B., Hayward R.A., Bates E.R. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation 2008, 118(12):1294-1303. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.703579.
3. Roland M., Torgerson D.J. What are pragmatic trials?. BMJ 1998, 316:285. http://dx.doi.org/10.1136/bmj.316.7127.285.
4. Compher C. Efficacy vs effectiveness. JPEN J Parenter Enteral Nutr 2010, 34(6):598-599. http://dx.doi.org/10.1177/0148607110381906.
5. Stanley K. Design of randomized controlled trials. Circulation 2007, 115:1164-1169. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.594945.
6. Stanley K. Evaluation of randomized controlled trials. Circulation 2007, 115:1819-1822. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.618603.
7. Price D., Chisholm A., van der Molen T., Roche N., Hillyer E.V., Bousquet J. Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness. Curr Allergy Asthma Rep 2011, 11(6):526-538. http://dx.doi.org/10.1007/s11882-011-0222-7.
8. Price D., Roche N., Martin R., Chisholm A. Feasibility and ethics. Am J Respir Crit Care Med 2013, 188:1368-1369. Respiratory Effectiveness Group Collaborators. http://dx.doi.org/10.1164/rccm.201307-1250LE.
9. Roche N., Reddel H.K., Agustì A., Bateman E.D., Krishnan J.A., Martin R.J., et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med 2013, 1:e29-e30. http://dx.doi.org/10.1016/S2213-2600(13)70199-1.
10. Concato J. Study design and "evidence" in patient-oriented research. Am J Respir Crit Care Med 2013, 187:1167-1172. http://dx.doi.org/10.1164/rccm.201303-0521OE.
11. Albert R. "Lies, damned lies. . ." and observational studies in comparative effectiveness research. Am J Respir Crit Care Med 2013, 187:1173-1177. http://dx.doi.org/10.1164/rccm.201212-2187OE.
12. Nichol A., Bailey M., Cooper D.J. Challenging issues in randomised controlled trials. Injury 2010, 41(Suppl.1):S20-S23. POLAR; EPO Investigators. http://dx.doi.org/10.1016/j.injury.2010.03.033.
13. Jaillon P. Controlled randomized clinical trials. Bull Acad Natl Med 2007, 191(4-5):739-756. [Article in French].
14. Price D., Hillyer E.V., van der Molen T. Efficacy versus effectiveness trials: informing guidelines for asthma management. Curr Opin Allergy Clin Immunol 2013, 13(1):50-57. http://dx.doi.org/10.1097/ACI.0b013e32835ad059.
15. US Preventive Services Task Force Guide to clinical preventive services: report of the US Preventive Services Task Force 1996, Williams & Wilkins, Baltimore, MD. 2nd ed.
16. Samet J. Measuring the effectiveness of inhaled corticosteroids for COPD is not easy!. Am J Respir Crit Care Med 2003, 168(1):1-2. http://dx.doi.org/10.1164/rccm.2304004.
17. British guideline on the management of asthma. A national clinical guideline May 2008, Revised June 2009. http://www.sign.ac.uk/guidelines/fulltext/101/index.html.
18. Reddel H., Taylor D.R., Bateman E.D., Boulet L.P., Boushey H.A., Busse W.W., et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009, 180:59-99. http://dx.doi.org/10.1164/rccm.200801-060ST.
19. GINA report. Global strategy for asthma management and prevention. Updated December 2012. http://www.ginasthma.org.
20. Vercken J. Randomized therapeutic trials of community-acquired lung diseases. Analysis of studies published between 1978 and 1988. Rev Pneumol Clin 1991, 47(1):21-27.
21. Altenburg J., de Graaff C.S., Stienstra Y., Sloos J.H., van Haren E.H., Koppers R.J., et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAm Med Assoc 2013, 309(12):1251-1259. http://dx.doi.org/10.1001/jama.2013.1937.
22. McKee M., Britton A., Black N., McPherson K., Sanderson C., Bain C. Methods in health services research: interpreting the evidence: choosing between randomised and non-randomised studies. BMJ 1999, 319:312-315. http://dx.doi.org/10.1136/bmj.319.7205.312.
23. Estellat C., Torgerson D.J., Ravaud P. How to perform a critical analysis of a randomised controlled trial. Best Pract Res Clin Rheumatol 2009, 23(2):291-303. http://dx.doi.org/10.1016/j.berh.2009.03.003.
24. Wood L., Egger M., Gluud L.L., Schulz K.F., Jüni P., Altman D.G., et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008, 336(7644):601-605. http://dx.doi.org/10.1136/bmj.39465.451748.AD.
25. Hollis S., Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999, 319:670-674. http://dx.doi.org/10.1136/bmj.319.7211.670.
26. Rothwell P. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet 2005, 365(9453):82-93. http://dx.doi.org/10.1016/S0140-6736(04)17670-8.
27. Annemans L, Aristides M, Kubin M. Real-life data: a growing need. ISPOR;. http://www.ispor.org/news/articles/oct07/rld.asp.
28. Järvinen T., Sievänen H., Kannus P., Jokihaara J., Khan K.M. The true cost of pharmacological disease prevention. BMJ 2011, 342:d2175. http://dx.doi.org/10.1136/bmj.d2175.
29. Krishnan J., Schatz M., Apter A.J. Acall for action: comparative effectiveness research in asthma. JAllergy Clin Immunol 2011, 127:123-127. http://dx.doi.org/10.1016/j.jaci.2010.08.032.
30. Ware J., Hamel M.B. Pragmatic trials - guides to better patient care?. NEngl J Med 2011, 364:1685-1687. http://dx.doi.org/10.1056/NEJMp1103502.
31. Herland K., Akselsen J.P., Skjønsberg O.H., Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?. Respir Med 2005, 99(1):11-19. http://dx.doi.org/10.1016/j.rmed.2004.03.026.
32. Scichilone N., Basile M., Battaglia S., Bellia V. What proportion of Chronic Obstructive Pulmonary Disease outpatients is eligible for inclusion in randomized clinical trials?. Respiration 2013 Nov 20, [Epub ahead of print].
33. Haughney J., Price D., Kaplan A., Chrystyn H., Horne R., May N., et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med 2008, 102(12):1681-1693. http://dx.doi.org/10.1016/j.rmed.2008.08.003.
34. Corrigan C. Asthma therapy: there are guidelines, and then there is real life. Prim Care Respir J 2011, 20:13-14. http://dx.doi.org/10.4104/pcrj.2011.00016.
35. Lötvall J., Akdis C.A., Bacharier L.B., Bjermer L., Casale T.B., Custovic A., et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. JAllergy Clin Immunol 2011, 127(2):355-360. http://dx.doi.org/10.1016/j.jaci.2010.11.037.
36. Rand C., Wright R.J., Cabana M.D., Foggs M.B., Halterman J.S., Olson L., et al. Mediators of asthma outcomes. JAllergy Clin Immunol 2012, 129(Suppl.3):S136-S141. http://dx.doi.org/10.1016/j.jaci.2011.12.987.
37. Smith J., Noble M.J., Musgrave S., Murdoch J., Price G.M., Barton G.R., et al. The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care. Thorax 2012, 67(12):1052-1060. http://dx.doi.org/10.1136/thoraxjnl-2012-202093.
38. Chaudhuri R., Livingston E., McMahon A.D., Thomson L., Borland W., Thomson N.C. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003, 168(11):1308-1311. http://dx.doi.org/10.1164/rccm.200304-503OC.
39. Tomlinson J., McMahon A.D., Chaudhuri R., Thompson J.M., Wood S.F., Thomson N.C. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 2005, 60(4):282-287. http://dx.doi.org/10.1136/thx.2004.033688.
40. Lange P., Parner J., Vestbo J., Schnohr P., Jensen G. A15-year follow-up study of ventilatory function in adults with asthma. NEngl J Med 1998, 339(17):1194-1200. http://dx.doi.org/10.1056/NEJM199810223391703.
41. Chaudhuri R., Livingston E., McMahon A.D., Lafferty J., Fraser I., Spears M., et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med 2006, 174(2):127-133. http://dx.doi.org/10.1164/rccm.200510-1589OC.
42. Eisner M., Iribarren C. The influence of cigarette smoking on adult asthma outcomes. Nicotine Tob Res 2007, 9:53-56. http://dx.doi.org/10.1080/14622200601078293.
43. Boulet L., FitzGerald J.M., McIvor R.A., Zimmerman S., Chapman K.R. Influence of current or former smoking on asthma management and control. Can Respir J 2008, 15(5):275-279.
44. Krishnan J., Davis S.Q., Charbeneau J.T., Holguin F., Naureckas E.T. Hospitalizations for asthma in the elderly in the U.S. in 2000 and 2005. Am J Respir Crit Care Med 2008 Apr, 177. American Thoracic Society international conference 2008, Abstract A667.
45. National Institutes of Health, National Heart Lung and Blood Institute. Morbidity & mortality: 2009 chart book on cardiovascular, lung, and blood diseases. http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf.
46. Moore W., Meyers D.A., Wenzel S.E., Teague W.G., Li H., Li X., et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010, 181:315-323. http://dx.doi.org/10.1164/rccm.200906-0896OC.
47. Ozyilmaz E., Kokturk N., Teksut G., Tatlicioglu T. Unsuspected risk factors of frequent exacerbations requiring hospital admission in chronic obstructive pulmonary disease. Int J Clin Pract 2013, 67:691-697. http://dx.doi.org/10.1111/ijcp.12150.
48. Fabbri L.M., Boyd C., Boschetto P., Rabe K.F., Buist A.S., Yawn B., et al. How to integrate multiple comorbidities in guideline development: article 10 in integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc 2012, 9:274-281. ATS/ERS Ad Hoc Committee on Integrating and Coordinating Efforts in COPD Guideline Development. http://dx.doi.org/10.1513/pats.201208-063ST.
49. Peters-Golden M., Swern A., Bird S.S., Hustad C.M., Grant E., Edelman J.M. Influence of body mass index on the response to asthma controller agents. Eur Respir J 2006, 27:495-503.
50. Boulet L.P., Boulay M.È. Asthma-related comorbidities. Expert Rev Respir Med 2011, 5:377-393. http://dx.doi.org/10.1586/ers.11.34.
51. Hawkins N.M., Wang D., Petrie M.C., Pfeffer M.A., Swedberg K., Granger C.B., et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail 2010, 12:557-565. http://dx.doi.org/10.1093/eurjhf/hfq040.
52. Brooks T.W., Creekmore F.M., Young D.C., Asche C.V., Oberg B., Samuelson W.M. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy 2007, 27:684-690.
53. Kunz R., Oxman A.D. The unpredictability paradox: review of empirical comparisons of randomised and nonrandomised clinical trials. BMJ 1998, 317:1185-1190. http://dx.doi.org/10.1136/bmj.317.7167.1185.
54. Giraud V., Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002, 19(2):246-251. http://dx.doi.org/10.1183/09031936.02.00218402.
55. Davies G., Pyke S., Kinmouth A.L. Effect of nonattenders on the potential of a primary care programme to reduce cardiovascular risk in the population. BMJ 1994, 309:1553-1556. http://dx.doi.org/10.1136/bmj.309.6968.1553.
56. Hunninghake D., Darby C.A., Probstfield J.L. Recruitment experience in clinical trials: literature summary and annotated bibliography. Control Clin Trials 1987, 8:6S-30S. http://dx.doi.org/10.1016/0197-2456(87)90004-3.
57. Horwitz R. Complexity and contradiction in clinical trial research. Am J Med 1987, 82:498-510. http://dx.doi.org/10.1016/0002-9343(87)90450-5.
58. Colditz G., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAm Med Assoc 1994, 271:698-702. http://dx.doi.org/10.1001/jama.1994.03510330076038.
59. Clemens J., Chuong J.J., Feinstein A.R. The BCG controversy. A methodological and statistical reappraisal. JAm Med Assoc 1983, 249:2362-2369. http://dx.doi.org/10.1001/jama.1983.03330410048027.
60. Wechsler M., Kelley J.M., Boyd I.O., Dutile S., Marigowda G., Kirsch I., et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. NEngl J Med 2011, 365(2):119-126. http://dx.doi.org/10.1056/NEJMoa1103319.
61. Ryan D., Price D., Musgrave S.D., Malhotra S., Lee A.J., Ayansina D., et al. Clinical and cost effectiveness of mobile phone supported self monitoring of asthma: multicentre randomised controlled trial. BMJ 2012, 344:e1756. 10.1136/bmj.e1756.
62. Konstantinou G. Pragmatic trials: how to adjust for the 'Hawthorne effect'?. Thorax 2012, 67:562. http://dx.doi.org/10.1136/thoraxjnl-2011-200657.
63. Baiardini I., Braido F., Bonini M., Compalati E., Canonica G.W. Why do doctors and patients not follow guidelines?. Curr Opin Allergy Clin Immunol 2009, 9:228-233. http://dx.doi.org/10.1097/ACI.0b013e32832b4651.
64. Pauwels R., Löfdahl C.G., Postma D.S., Tattersfield A.E., O'Byrne P., Barnes P.J., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. NEngl J Med 1997, 337(20):1405-1411. http://dx.doi.org/10.1056/NEJM199711133372001.
65. Bjermer L., Bisgaard H., Bousquet J., Fabbri L.M., Greening A.P., Haahtela T., et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003, 327(7420):891. http://dx.doi.org/10.1136/bmj.327.7420.891.
66. Bateman E., Boushey H.A., Bousquet J., Busse W.W., Clark T.J., Pauwels R.A., et al. Can guideline-defined asthma control be achieved? the gaining optimal asthma control study. Am J Respir Crit Care Med 2004, 170(8):836-844. http://dx.doi.org/10.1164/rccm.200401-033OC.
67. Feudtner C., Schreiner M., Lantos J.D. Risks (and benefits) in comparative effectiveness research trials. NEngl J Med 2013, 369(10):892-894. http://dx.doi.org/10.1056/NEJMp1309322.
68. Barnes N., Menzies-Gow A., Mansur A.H., Spencer D., Percival F., Radwan A., et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. JAsthma 2013, 50(5):529-536. http://dx.doi.org/10.3109/02770903.2013.790419.
69. Folli C., Chiappori A., Pellegrini M., Garelli V., Riccio A.M., De Ferrari L., et al. COPD treatment: real life and experimental effects on peripheral NK cells, their receptors expression and their IFN-γ secretion. Pulm Pharmacol Ther 2012, 25(5):371-376. http://dx.doi.org/10.1016/j.pupt.2012.06.009.
70. Öztürk C., Kaya A., Bilgin C., Yücesoy L., Ikidaǧ B., Demirel M., et al. Evaluation of inhaler technique and patient satisfaction with fixed-combination budesonide/formoterol dry-powder inhaler in chronic obstructive pulmonary disease (COPD): data on real-life clinical practice in Turkey. Tuberk Torak 2012, 60(4):301-313. http://dx.doi.org/10.5578/tt.4634.
71. Bourbeau J., Saad N., Joubert A., Ouellet I., Drouin I., Lombardo C., et al. Making collaborative self-management successful in COPD patients with high disease burden. Respir Med 2013, 107(7):1061-1065. http://dx.doi.org/10.1016/j.rmed.2013.03.003.
72. Braido F., Brusselle G., Ingrassia E., Nicolini G., Price D., Roche N., et al. International cross-sectional and longitudinal assessment on asthma control in European adult patients - the LIAISON study protocol. BMC Pulm Med 2013, 13:18. http://dx.doi.org/10.1186/1471-2466-13-18.
73. Price D., Asukai Y., Ananthapavan J., Malcolm B., Radwan A., Keyzor I. AUK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use. Appl Health Econ Health Policy 2013, 11(3):259-274. http://dx.doi.org/10.1007/s40258-013-0021-5.
74. Scichilone N., Spatafora M., Battaglia S., Arrigo R., Benfante A., Bellia V. Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations. JAsthma Allergy 2013, 6:11-21. http://dx.doi.org/10.2147/JAA.S14743.
75. van Nooten F., Stern S., Braunstahl G.J., Thompson C., Groot M., Brown R.E. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. JMed Econ 2013, 16(3):342-348. http://dx.doi.org/10.3111/13696998.2012.756398.
76. Tunis S., Stryer D.B., Clancy C.M. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAm Med Assoc 2003, 290:1624-1632. http://dx.doi.org/10.1001/jama.290.12.1624.
77. Zwarenstein M., Treweek S., Gagnier J.J., Altman D.G., Tunis S., Haynes B., et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008, 337:a2390. http://dx.doi.org/10.1136/bmj.a2390.
78. Chalkidou K., Tunis S., Whicher D., Fowler R., Zwarenstein M. The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research. Clin Trials 2012, 9:436-446. http://dx.doi.org/10.1177/1740774512450097.
79. Sarrazin M., Rosenthal G.E. Finding pure and simple truths with administrative data. JAm Med Assoc 2012, 307:1433-1435. http://dx.doi.org/10.1001/jama.2012.404.
80. Di Marco F., Tantucci C., Pellegrino G., Centanni S. Chronic obstructive pulmonary disease diagnosis: the simpler the better? Not always. Eur J Intern Med 2013, 24:199-202. http://dx.doi.org/10.1016/j.ejim.2013.01.008.
81. Bombardier C., Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?. Ann Rheum Dis 1999, 58(Suppl.1):I82-I85. http://dx.doi.org/10.1136/ard.58.2008.i82.
82. Concato J., Shah N., Horwitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. NEngl J Med 2000, 342:1887-1892. http://dx.doi.org/10.1056/NEJM200006223422507.
83. Rabe K., Adachi M., Lai C.K., Soriano J.B., Vermeire P.A., Weiss K.B., et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. Allergy Clin Immunol 2004, 114(1):40-47. http://dx.doi.org/10.1016/j.jaci.2004.04.042.
84. Melani A., Bonavia M., Cilenti V., Cinti C., Lodi M., Martucci P., et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011, 105(6):930-938. http://dx.doi.org/10.1016/j.rmed.2011.01.005.
85. Brocklebank D., Ram F., Wright J., Barry P., Cates C., Davies L., et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001, 5(26):1-149.
86. Dolovich M., Ahrens R.C., Hess D.R., Anderson P., Dhand R., Rau J.L., et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005, 127(1):335-371. http://dx.doi.org/10.1378/chest.127.1.335.
87. National Asthma Education And Prevention Program Expert panel report 3: guidelines for the diagnosis and management of asthma 2007, Full report. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.
88. Papi A., Haughney J., Virchow J.C., Roche N., Palkonen S., Price D. Inhaler devices for asthma: a call for action in a neglected field. Eur Respir J 2011, 37(5):982-985. http://dx.doi.org/10.1183/09031936.00150910.
89. Price D., Chrystyn H., Kaplan A., Haughney J., Román-Rodríguez M., Burden A., et al. Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. Allergy Asthma Immunol Res 2012, 4(4):184-191. http://dx.doi.org/10.4168/aair.2012.4.4.184.
90. Price D., Haughney J., Sims E., Ali M., von Ziegenweidt J., Hillyer E.V., et al. Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. JAsthma Allergy 2011, 4:37-47. 10.2147/JAA.S17709.
91. Price D., Roche N., Christian Virchow J., Burden A., Ali M., Chisholm A., et al. Device type and real-world effectiveness of asthma combination therapy: an observational study. Respir Med 2011, 105(10):1457-1466. http://dx.doi.org/10.1016/j.rmed.2011.04.010.
92. Müller V., Gálffy G., Eszes N., Losonczy G., Bizzi A., Nicolini G., et al. Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation. BMC Pulm Med 2011, 11:40. http://dx.doi.org/10.1186/1471-2466-11-40.
93. Santus P., Picciolo S., Proietto A., Falcone F., Mangiacavallo A., Pellegrino G., et al. Doctor-patient relationship: a resource to improve respiratory diseases management. Eur J Intern Med 2012, 23:442-446. http://dx.doi.org/10.1016/j.ejim.2012.04.004.
94. Price D., Robertson A., Bullen K., Rand C., Horne R., Staudinger H. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med 2010, 10:1. http://dx.doi.org/10.1186/1471-2466-10-1.
95. Price D., Musgrave S.D., Shepstone L., Hillyer E.V., Sims E.J., Gilbert R.F., et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. NEngl J Med 2011, 364(18):1695-1707. http://dx.doi.org/10.1056/NEJMoa1010846.
96. Ducharme F., Noya F.J., Allen-Ramey F.C., Maiese E.M., Gingras J., Blais L. Clinical effectiveness of inhaled corticosteroids versus montelukast in children with asthma: prescription patterns and patient adherence as key factors. Curr Med Res Opin 2012, 28(1):111-119. http://dx.doi.org/10.1185/03007995.2011.640668.
97. van Staa T., Leufkens H.G., Zhang B., Smeeth L. Acomparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example. PLoS Med 2009, 6:e1000194. http://dx.doi.org/10.1371/journal.pmed.1000194.
98. Rizzo J., Powe N.R. Methodological hurdles in conducting pharmacoeconomic studies. Pharmacoeconomics 1999, 15:339-355. http://dx.doi.org/10.2165/00019053-199915040-00002.
99. Stempel D., Roberts C.S., Stanford R.H. Treatment patterns in the months prior to and after asthma-related emergency department visit. Chest 2004, 126(1):75-80. http://dx.doi.org/10.1378/chest.126.1.75.
100. Molimard M., Raherison C., Lignot S., Depont F., Abouelfath A., Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. Aerosol Med 2003, 16(3):249-254. http://dx.doi.org/10.1089/089426803769017613.
101. Austin P., Grootendorst P., Anderson G.M. Acomparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007, 26(4):734-753. http://dx.doi.org/10.1002/sim.2580.
102. Thomas M., Cleland J., Price D. Database studies in asthma pharmacoeconomics: uses, limitations and quality markers. Expert Opin Pharmacother 2003, 4:351-358. http://dx.doi.org/10.1517/14656566.4.3.351.
103. Ernst E., Canter P.H. Limitations of "pragmatic" trials. Postgrad Med J 2005, 81:203. http://dx.doi.org/10.1136/pgmj.2004.026807.
104. Resch K.L. Pragmatic trials: propaganda or research tool?. Focus Altern Complement Ther 2005, 10:181-183. http://dx.doi.org/10.1211/fact.10.3.0006.
105. Kent D., Kitsios G. Against pragmatism: on efficacy, effectiveness and the real world. Trials 2009, 10:48. http://dx.doi.org/10.1186/1745-6215-10-48.
106. Haut E., Pronovost P.J. Surveillance bias in outcomes reporting. JAm Med Assoc 2011, 305(23):2462-2463. http://dx.doi.org/10.1001/jama.2011.822.
107. Pierce C., Haut E.R., Kardooni S., Chang D.C., Efron D.T., Haider A., et al. Surveillance bias and deep vein thrombosis in the National Trauma Data Bank: the more we look, the more we find. JTrauma 2008, 64(4):932-937. http://dx.doi.org/10.1097/TA.0b013e318166b808.
108. Salas M., Hofman A., Stricker B.H. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999, 149:981-983. http://dx.doi.org/10.1093/oxfordjournals.aje.a009758.
109. Hennekens C., Buring J.E. Epidemiology in medicine 1987, 272-286. Little, Brown & Co, Boston, MA.
110. Blais L., Ernst P., Suissa A. Confounding by indication and channeling over time: the risks of beta2-agonists. Am J Epidemiol 1996, 144:1161-1169. http://dx.doi.org/10.1093/oxfordjournals.aje.a008895.
111. Kozyrskyj A., Ernst P., Becker A.B. Increased risk of childhood asthma from antibiotic use in early life. Chest 2007, 131(6):1753-1759. http://dx.doi.org/10.1378/chest.06-3008.
112. Alm B., Erdes L., Möllborg P., Pettersson R., Norvenius S.G., Aberg N., et al. Neonatal antibiotic treatment is a risk factor for early wheezing. Pediatrics 2008, 121(4):697-702. http://dx.doi.org/10.1542/peds.2007-1232.
113. Almqvist C., Wettermark B., Hedlin G., Ye W., Lundholm C. Antibiotics and asthma medication in a large register-based cohort study - confounding, cause and effect. Clin Exp Allergy 2012, 42(1):104-111. http://dx.doi.org/10.1111/j.1365-2222.2011.03850.x.
114. Heintze K., Petersen K.U. The case of drug causation of childhood asthma: antibiotics and paracetamol. Eur J Clin Pharmacol 2013, 69(6):1197-1209. http://dx.doi.org/10.1007/s00228-012-1463-7.
115. Cullinan P., Harris J., Mills P., Moffat S., White C., Figg J., et al. Early prescriptions of antibiotics and the risk of allergic disease in adults: a cohort study. Thorax 2004, 59(1):11-15.
116. Sin D., Tu J.V. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164(4):580-584. http://dx.doi.org/10.1164/ajrccm.164.4.2009033.
117. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003, 168(1):49-53. http://dx.doi.org/10.1164/rccm.200210-1231OC.
118. Horwitz R., Viscoli C.M., Clemens J.D., Sadock R.T. Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med 1990, 89:6308. http://dx.doi.org/10.1016/0002-9343(90)90182-D.
119. von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P., et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007, 370(9596):1453-1457. http://dx.doi.org/10.1016/S0140-6736(07)61602-X.
120. Begg C., Cho M., Eastwood S., Horton R., Moher D., Olkin I., et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAm Med Assoc 1996, 276(8):637-639. http://dx.doi.org/10.1001/jama.276.8.637.
121. Campbell M., Elbourne D.R., Altman D.G. CONSORT statement: extension to cluster randomised trials. BMJ 2004, 328:702-708. http://dx.doi.org/10.1136/bmj.328.7441.702.
122. Campbell M., Piaggio G., Elbourne D.R., Altman D.G. Consort 2010 statement: extension to cluster randomised trials. BMJ 2012, 345:e5661. CONSORT Group. http://dx.doi.org/10.1136/bmj.e5661.
123. Perkins S., Tu W., Underhill M.G., Zhou X.H., Murray M.D. The use of propensity scores in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 2000, 9(2):93-101. http://dx.doi.org/10.1002/(SICI)1099-1557(200003/04)9:2%3C93::AID-PDS474%3E3.0.CO;2-I.
124. Newgard C., Hedges J.R., Arthur M., Mullins R.J. Advanced statistics: the propensity score - a method for estimating treatment effect in observational research. Acad Emerg Med 2004, 11(9):953-961.
125. Rosenbaum P., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55. http://dx.doi.org/10.1093/biomet/70.1.41.
126. Rosenbaum P., Rubin D.B. Reducing bias in observational studies using subclassification on the propensity score. JAm Stat Assoc 1984, 79:516-524. http://dx.doi.org/10.1080/01621459.1984.10478078.
127. D'Agostino R. Tutorial in biostatistics - propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17:2265-2281. http://dx.doi.org/10.1002/(SICI)1097-0258(19981015)17:19%3C2265::AID-SIM918%3E3.0.CO;2-B.
128. Little R., Rubin D.B. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health 2000, 21:121-145. http://dx.doi.org/10.1146/annurev.publhealth.21.1.121.
129. Rubin D. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997, 127:757-763. http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00064.
130. Heinze G., Jüni P. An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J 2011, 32(14):1704-1708. http://dx.doi.org/10.1093/eurheartj/ehr031.
131. Barnes N., Price D., Colice G., Chisholm A., Dorinsky P., Hillyer E.V., et al. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study. Clin Exp Allergy 2011, 41(11):1521-1532. http://dx.doi.org/10.1111/j.1365-2222.2011.03820.x.
132. Larsson K., Janson C., Lisspers K., Jørgensen L., Stratelis G., Telg G., et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease. The PATHOS study. JIntern Med 2013, 273(6):584-594. http://dx.doi.org/10.1111/joim.12067.